COMMUNICABLE THROUGH BLOOD PRODUCTS,NEEDLE PRICKS, SCRATCH, SEXUAL CONTACT & SOME TIMES MATERNAL-FETAL TRANSMISSION, NOT BY ORAL ROUTE.
RISK FACTORS
β’ Health care workers/other occupational risks
β’ HCV transmitted through blood or its products; in 40%, mode unknown
β’ Hemodialysis
β’ Recipients of blood and/or blood products (esp. prior to 1992)
β’ IV drug users 60-70% of new infections
β’ Sexually active homosexual males (much more likely with hepatitis B than with C)
β’ Household exposure
β’ Intimate exposure
β’ Positive needlestick
β’ Transplanted organs
β’ Snorting cocaine
β’ Recent body piercing; tattoos less likely, role controversial
β’ HIV positivity increases risk of hepatitis C or C virus infection in coinfected patients
β’ Perinatal transmission of neonate of hepatitis B infected mother rare with HCV unless HIV positive
Medical Care: The goals of treatment of chronic HCV infection are to (1) achieve sustained eradication of HCV (ie, sustained virological response [SVR]), defined as the persistent absence of HCV RNA in serum 6 months or more after completing antiviral treatment and (2) prevent progression to cirrhosis, HCC, and decompensated liver disease requiring LT.
At week 12 of treatment, the patient should be evaluated for an early virological response by repeating the quantitative HCV RNA and IFN-associated thyroid dysfunction screening. If the HCV RNA level is undetectable or if a greater than 2-log-fold reduction in HCV RNA level is present, therapy should be continued because, according to Fried et al in 2002, up to 65% of patients go on to develop an SVR. Conversely, if an early virological response is not present, treatment should be stopped because the chance of developing a sustained response of HCV eradication is less than 3%. Poynard et al reported in 1998 that the one exception is in the context of clinical trials or treatment of recurrent HCV infection in liver transplant recipients; improved fibrosis scores have been reported in patients in whom the virus has not been eradicated, thus identifying a subgroup of patients who may benefit from maintenance therapy.
The HCV RNA level should be rechecked 6 months after the completion of treatment, and, if detectable, the patient has relapsed and should be considered for an alternative treatment. If HCV RNA is undetectable and test results remain negative, the patient has developed an SVR.
Antiviral therapy for chronic hepatitis C is currently recommended for patients with elevated serum ALT levels who (1) are older than 18 years; (2) have positive findings for HCV antibody and serum HCV RNA; (3) have liver biopsy findings consistent with a diagnosis of chronic hepatitis, although a biopsy is not essential; and (4) have no contraindications for treatment.
The treatment of hepatitis C has evolved over the years. The early pivotal studies of IFN monotherapy, IFN in which polyethylene glycol (PEG) molecules are added (ie, PEG-IFN) monotherapy, and combination therapy with ribavirin (with either IFN or PEG-IFN) are described first, after which therapy for special patient groups will be discussed. Additionally, the impact of IFN on the development of HCC will be briefly discussed.
IFN therapy with and without ribavirin
Although the short courses of standard IFN monotherapy first introduced in the 1980s by Hoofnagle et al (1986), Davis et al (1989), and Di Bisceglie et al (1989) led to sustained improvement in liver disease and loss of virus in less than 10% of patients, these therapies were the first to cure chronic viral hepatitis. A major advance in the treatment of chronic hepatitis C was the addition of the oral nucleoside analogue ribavirin to the IFN regimen. As reported in the landmark 1998 studies by McHutchison et al and Poynard et al, IFN alfa-2b and ribavirin combination therapy for 6-12 months resulted in sustained eradication rates of 30-40%. However, patients with HCV genotype 1 who were treated for 12 months had a much less favorable response to therapy with IFN and ribavirin compared with patients infected with genotypes 2 and 3, in whom a 6-month course of therapy was sufficient.
IFN monotherapy appears to play a role in the treatment of acute HCV infection. In 2001, Jaeckel et al reported that treatment with IFN alfa-2b prevented chronic infection in 98% of a group of 44 German patients with acute hepatitis C. In this study, patients received 5 million U/d of IFN alfa-2b subcutaneously for 4 weeks and then 3 times per week for another 20 weeks; the IFN alfa-2b was well tolerated in all patients but one. Because spontaneous resolution is common, no definitive timing of therapy can be recommended; although waiting 2-4 months after the onset of illness seems reasonable.
The 2 most frequently used recombinant IFN preparations in clinical trials are IFN alfa-2b (Intron-A; Schering-Plough, Kenilworth, NJ) and IFN alfa-2a (Roferon; Hoffmann-La Roche, Basel, Switzerland), which differ from each other by only a single amino acid residue. IFN alfacon-1 (Infergens; Amgen, Thousand Oaks, Calif), or consensus IFN, is a genetically engineered compound synthesized by combining the most common amino acid sequences from all 12 naturally occurring IFNs. It has greater cytokine-induction, antiviral, antiproliferative, natural killer cell, and gene-induction activities than both IFN alfa-2a and IFN alfa-2b on an equal-mass basis. However, initial studies of the recommended consensus IFN dose of 9 mcg in IFN-naive patients with chronic hepatitis C, such as that by Tong et al from 1997, have resulted in viral response rates similar to those of standard IFN-alfa monotherapy.
PEG-IFN monotherapy
Recent developments in IFN technology have led to the development of long-lasting IFNs in which PEG molecules are added to IFN. These new PEG-IFNs have better sustained absorption, a slower rate of clearance, and a longer half-life than those of unmodified IFN. They permit more convenient once-weekly dosing. The FDA has approved PEG-IFNs for the treatment of chronic hepatitis C.
The 2 PEG-IFN preparations currently available are (1) PEG-Intron (Schering-Plough), which consists of IFN alfa-2b attached to a single 12-kd PEG chain and is metabolized predominantly by the liver, and (2) Pegasys (Hoffmann-La Roche), which consists of IFN alfa-2a attached to a 40-kd branched PEG molecule. Note that pegylated alfa-2b is excreted by the kidneys.
Several reports have documented the improved SVR with PEG-IFN monotherapy. In a 2000 randomized study of patients with chronic hepatitis C, Zeuzem et al found that PEG-IFN alfa-2a at 180 mcg subcutaneously administered once per week was associated with a higher rate of virologic response than IFN alfa-2a at 6 million U subcutaneously administered 3 times per week for 12 weeks followed by 3 million U 3 times per week for 36 weeks. Findings were 69% versus 28% (P = .001) at week 48 of therapy and 39% versus 19% (P = .001) at week 72 of therapy. Drug discontinuation in these treatment-naive patients and the frequencies of dose reduction were similar in the 2 treatment groups.
In 2000, Heathcote and colleagues reported on the use of PEG-IFN alfa-2a in a controlled trial of subjects with cirrhosis. The SVR rate was 30% after 48 weeks of therapy with 180 mcg, compared with 8% for patients treated with standard IFN alfa. Adverse effects did not significantly increase with the pegylated product.
PEG-IFN therapy with ribavirin
As previously described with IFN alfa monotherapy, the addition of ribavirin to PEG-IFN has heralded a new era in the treatment of chronic HCV, resulting in 3 landmark trials: Manns et al from 2001, Fried et al from 2002, and Hadziyannis et al from 2004.
In 2001, Manns et al compared PEG-IFN alfa-2b plus ribavirin with IFN alfa-2b plus ribavirin in 1530 subjects with chronic hepatitis C. Subjects were randomly assigned to 3 groups as follows: (1) IFN alfa-2b at 3 million U subcutaneously 3 times per week plus ribavirin at 1000-1200 mg/d orally, (2) PEG-IFN alfa-2b at 1.5 mcg/kg/wk plus ribavirin at 800 mg/d, and (3) PEG-IFN alfa-2b at 1.5 mcg/kg/wk for 4 weeks and then 0.5 mcg/kg/wk plus ribavirin at 1000-1200 mg/d for 48 weeks.
The SVR rate was significantly higher in the higher-dose PEG-IFN group (274 [54%] of 511 subjects) than in the lower-dose PEG-IFN (244 [47%] of 514 subjects; P = .01) or IFN (235 [47%] of 505 subjects; P = .01) groups. Among patients with HCV genotype 1 infection, the corresponding SVR rates were 42% (145 of 348 patients), 34% (118 of 349 patients), and 33% (114 of 343 patients). The rates for patients with genotype 2 and 3 infections were approximately 80% for all treatment groups. Adverse-effect profiles were similar among the treatment groups. Secondary analyses identified body weight and HCV RNA viral load less than 1 million copies per milliliter as important predictors of SVR. When the dose was optimized for the patient's body weight, with a dose of more than 10.6 mg/kg of ribavirin daily, the SVR with IFN regimens was 61% for all genotypes, 48% for genotype 1, and 88% for genotypes 2 and 3.
In 2002, Fried at al compared the efficacy and safety of PEG-IFN alfa-2a plus ribavirin to IFN alfa-2b plus ribavirin and PEG-IFN alfa-2a monotherapy in a multicenter, randomized, controlled trial. A total of 1121 subjects were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 mcg of PEG-IFN alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly PEG-IFN alfa-2a plus daily placebo, or 3 million U of IFN alfa-2b thrice weekly plus daily ribavirin for 48 weeks.
This study showed that a significantly higher proportion of subjects who received PEG-IFN alfa-2a plus ribavirin had an SVR compared with subjects who received IFN alfa-2b plus ribavirin (56% vs 44%, P <.001) or PEG-IFN alfa-2a alone (56% vs 29%, P <.001). The SVR rates for patients with HCV genotype 1 were 46%, 36%, and 21%, respectively, for the 3 regimens. Among patients with HCV genotype 1 and high baseline levels of HCV RNA, the SVR rates were 41%, 33%, and 13%, respectively. The overall safety profiles of the 3 treatment regimens were similar; the prevalence of influenzalike symptoms and depression was lower in the groups receiving PEG-IFN alfa-2a than in the group receiving IFN alfa-2b plus ribavirin. Overall, once-weekly PEG-IFN alfa-2a plus ribavirin was tolerated as well as IFN alfa-2b plus ribavirin and produced significant improvements in the SVR rate compared with IFN alfa-2b plus ribavirin or PEG-IFN alfa-2a alone.
In 2004, Hadziyannis et al reported the efficacy and safety of 24 or 48 weeks of treatment with PEG-IFN alpha-2a plus a low or standard dose of ribavirin in a randomized, double-blinded trial. The 1311 subjects were randomized to PEG-IFN alfa-2a at 180 mcg/wk for 24 or 48 weeks plus a low dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. An SVR was defined as undetectable HCV RNA at the end of treatment and during 12-24 weeks of follow-up.
Their study showed that in subjects infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and that standard-dose ribavirin was statistically superior to low-dose ribavirin. In subjects with HCV genotype 1, absolute differences in SVR rates between 48 and 24 weeks of treatment were 11.2% (95% confidence interval [CI], 3.6-18.9%) and 11.9% (CI, 4.7-18.9%), respectively, between standard- and low-dose ribavirin. SVR rates for PEG-IFN alfa-2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59-68%) overall and 52% (CI, 46-58%) in subjects with HCV genotype 1. In subjects with HCV genotypes 2 or 3, the SVR rates in the 4 treatment groups were not statistically significantly different.
In conclusion, treatment with PEG-IFN alfa-2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotype 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.
Currently, no studies have compared PEG-IFN alfa-2b plus ribavirin versus PEG-IFN alfa-2a plus ribavirin. According to the 2002 US National Institutes of Health consensus statement on the management of hepatitis C, standard of care for the treatment of hepatitis C is PEG-IFN with ribavirin for 48 weeks in patients with genotype 1 and is 24 weeks for patients with genotype 2 or 3.
Adverse effects are common with IFN and ribavirin combination therapy, with approximately 75% of patients experiencing one or more of the following:
" Interferon - Hematological complications (ie, neutropenia, thrombocytopenia), neuropsychiatric complications (ie, memory and concentration disturbances, visual disturbances, headaches, depression, irritability), flulike symptoms, metabolic complications (ie, hypothyroidism, hyperthyroidism, low-grade fever), gastrointestinal complications (ie, nausea, vomiting, weight loss), dermatological complications (ie, alopecia), and pulmonary complications (ie, interstitial fibrosis)
" Ribavirin - Hematological complications (ie, hemolytic anemia), reproductive complications (ie, birth defects), and metabolic complications (ie, gout)
Growth factors such as granulocyte-stimulating factor and erythropoietin are frequently used to counteract the adverse hematological effects of IFN and ribavirin, respectively. Despite the encouraging results reported by Afdhal et al in 2004 and Van Thiel et al in 1995, cost-effectiveness data supporting their routine use as a means of avoiding IFN and ribavirin dose reductions are insufficient.
In patients who are at risk of depression or who develop depression during treatment, any antidepressant is better than none. Because available evidence suggests that all antidepressants will have an effect, Schaefer et al reported in 2002 that treatment must be individualized on the basis of adverse effect profile, drug-to-drug interactions, and general considerations (eg, speed of onset, efficacy).
Special patient groups
HIV-HCV co-infection
Of persons infected with HIV, 30-50% are co-infected with HCV. Co-infection with HIV both accelerates the clinical progression of hepatitis C and increases the risk of perinatal HCV transmission from 5% (range, 3-8%) to 17% (range, 7-36%). Two 2004 studies have supported the use of PEG-IFN alfa-2a plus ribavirin for HIV patients with chronic HCV infection.
In the first, Torriani et al randomized 868 subjects with HIV and HCV co-infection (who had not previously been treated with IFN or ribavirin) to receive 1 of 3 regimens: (1) PEG-IFN alfa-2a (180 mcg/wk) plus ribavirin (800 mg/d), (2) PEG-IFN alfa-2a plus placebo, or (3) IFN alfa-2a (3 million IU 3 times/wk) plus ribavirin. Subjects were treated for 48 weeks and followed for an additional 24 weeks. The primary endpoint was an SVR (defined as a serum HCV RNA level <50 IU/mL at the end of 72-wk follow-up).
Their study showed the overall SVR rate was significantly higher among the recipients of PEG-IFN alfa-2a plus ribavirin than among those assigned to IFN alfa-2a plus ribavirin (40% vs 12%, P <.001) or PEG-IFN alfa-2a plus placebo (40% vs 20%, P <.001). Among subjects infected with HCV genotype 1, the SVR rates were 29% with PEG-IFN alfa-2a plus ribavirin, 14% with PEG-IFN alfa-2a plus placebo, and 7% with IFN alfa-2a plus ribavirin. The corresponding rates among subjects infected with HCV genotype 2 or 3 were 62%, 36%, and 20%.
Neutropenia and thrombocytopenia were more common among subjects treated with regimens that contained PEG-IFN alfa-2a, and anemia was more common among subjects treated with regimens containing ribavirin. In conclusion, among patients co-infected with HIV and HCV, the combination of PEG-IFN alfa-2a plus ribavirin is significantly more effective than either IFN alfa-2a plus ribavirin or PEG-IFN alfa-2a monotherapy.
For the second, Chung et al conducted a multicenter, randomized trial of patients co-infected with HIV and HCV. Sixty-six subjects were randomly assigned to receive 180 mcg of PEG-IFN alfa-2a weekly for 48 weeks, and 67 subjects were assigned to receive 6 million IU of IFN alfa-2a 3 times weekly for 12 weeks, followed by 3 million IU 3 times weekly for 36 weeks. Both groups received ribavirin according to a dose-escalation schedule. This study showed treatment with PEG-IFN and ribavirin was associated with a significantly higher SVR rate (an HCV RNA level <60 IU/mL 24 wk after completion of therapy) than treatment with IFN and ribavirin (27% vs 12%, P = .03). In the group given PEG-IFN and ribavirin, only 7 (14%) of 51 subjects with HCV genotype 1 infection had an SVR, compared with 11 (73%) of 15 subjects with an HCV genotype other than 1 (P <.001).
An important finding from the study was histologic improvement in 35% of subjects with no virologic response who underwent liver biopsy, suggesting that the effects of IFN and ribavirin on hepatic histology may be independent of its antiviral activity. In conclusion, in persons co-infected with HIV and HCV, the combination of PEG-IFN and ribavirin is superior to the combination of IFN and ribavirin in the treatment of chronic hepatitis C. These regimens may provide clinical benefit, even in the absence of virologic clearance.
No trials have compared PEG-IFN alfa-2a plus ribavirin with PEG-IFN alfa-2b plus ribavirin in patients with chronic hepatitis C and HIV infection. However, in a 2004 Spanish, open-label, randomized study comparing PEG-IFN alfa-2b plus ribavirin with IFN alfa-2b plus ribavirin, Laguno and colleagues reported SVRs were significantly better with the pegylated combination (44% vs 21%).
HCV-HBV co-infection
This form of co-infection, in the absence of HIV infection, is relatively uncommon in the United States, and optimal treatment regimens have not been established. However, 2 important studies are worth mentioning.
In 2001, Villa et al reported that 9 million U of standard IFN thrice weekly for 3 months could clear HCV in 31% of patients.
In 2003, Liu et al used standard IFN and ribavirin and discovered that sustained HCV eradication was achieved at rates comparable with patients with HCV alone and, interestingly, up to 21% of their patients lost the hepatitis B surface antigen. Given the increasing efficacy of PEG-IFN over standard IFN, these investigators are currently conducting a multicenter study using PEG-IFN and ribavirin on this group of co-infected patients.
African Americans and ethnic minorities
Several small studies have reported a lower response rate to IFN alfa among black patients with chronic hepatitis C infection than among white patients. The increased prevalence of infection with HCV genotype 1, which is associated with a lower response rate than other genotypes, has been suggested as the cause.
Muir et al treated 100 black patients and 100 non-Hispanic white patients with chronic hepatitis C with PEG-IFN alfa-2b and ribavirin for 48 weeks. Enrollment was controlled so the 2 groups had similar proportions of patients with genotype 1 infection. The primary endpoint was an SVR, defined as a negative test result for serum HCV RNA 6 months after the completion of therapy. In both cohorts, 98% of subjects had genotype 1 infection. The SVR rate was higher among non-Hispanic white subjects than among black subjects (52% vs 19%, P <.001). The black subjects also had significantly lower rates of virologic response at 12 weeks and at the end of treatment.
Multivariate analyses examining sociodemographic and clinical characteristics found that black race was the only variable significantly associated with the difference in response rates. In conclusion, black patients with chronic hepatitis C have a lower rate of response to treatment with PEG-IFN alfa-2b and ribavirin than non-Hispanic white patients, a difference that is not explained by differences in the viral genotype.
Hepburn et al recently analyzed data from 661 patients from 2 multicenter trials to determine predictors of successful viral eradication and the role of ethnicity. After performing multiple logistic regression analyses adjusted for factors known to impact outcome (eg, genotype), the authors reported that Asians were more likely to respond to treatment, whereas Hispanics and African Americans were less likely, in comparison to whites.
End-stage renal disease
HCV is prevalent in patients with end-stage renal disease and can also be an important cause of renal failure. Treatment of HCV infection in patients with end-stage renal disease is problematic because ribavirin is contraindicated and IFN monotherapy is not as effective as combination therapy. IFN doses also frequently have to be reduced. Before undergoing kidney transplantation, patients are frequently referred for consideration of HCV treatment and liver-kidney transplantation in the event of having silent-but-advanced liver disease. Under these circumstances, liver biopsies are frequently performed to stage the degree of fibrosis, and, if cirrhosis is present and the patient is asymptomatic, he or she is frequently considered for combined liver-kidney transplantation. However, because IFN is contraindicated after kidney or kidney-liver transplantation, attempting to eradicate HCV in such patients prior to organ transplantation is recommended.
Fabrizi et al evaluated the efficacy of IFN monotherapy in dialysis patients with chronic hepatitis C by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcome was an SVR, and the secondary outcome was the dropout rate. The authors identified 14 clinical trials (269 unique patients); 2 were controlled studies. The mean overall estimates for the SVR and dropout rates were 37% (95% CI, 28-48) and 17% (95% CI, 10-28), respectively. The most frequent adverse effects requiring interruption of treatment were flulike symptoms (17%), neurological symptoms (21%), and gastrointestinal symptoms (18%). The overall weighted estimate for SVR in patients with HCV genotype 1 was 30.6% (95% CI, 20.9-48). In the subgroup of clinical trials (n = 5) with standard IFN administration (3 million U thrice weekly, subcutaneous route, 24-wk treatment), the overall mean estimate of SVR was 39% (95% CI, 25-56). The studies were heterogeneous with regard to SVR and dropout rate.
In conclusion, tolerance to initial IFN monotherapy was lower in dialysis patients than in nonuremic patients with chronic hepatitis C. However, more than one third of hemodialysis patients with chronic hepatitis C have been successfully treated with IFN. A longer duration of IFN monotherapy does not appear to have a beneficial effect on the response rate. Further studies are warranted to define the optimal antiviral regimen for chronic hepatitis C in patients on dialysis.
Organ transplantation
IFN is contraindicated for HCV treatment after organ transplantation because of its high risk of precipitating rejection, in part due to up-regulation of the HLA system by IFN. However, allograft rejection is uncommon in liver transplant recipients with recurrent HCV infection who are treated with IFN-based therapies. As noted by Forman et al in 2002, recurrent HCV infection is universal after LT, can lead to cirrhosis in 30% of patients within 5 years, and is emerging as the most common cause of retransplantation in the United States.
Since 1996, several pilot studies have been conducted to evaluate IFN-based therapies for recurrent HCV infection. One of the most important of these was reported by Samuel et al in 2003, who randomized subjects to receive either no treatment or therapy with IFN alfa-2b (3 million U 3 times/wk) plus 1000-1200 mg/d of ribavirin for 1 year. Subjects were followed for 6 months after the end of treatment. The primary endpoint was loss of HCV RNA 6 months after the end of treatment.
Fifty-two subjects were randomized to receive either treatment (n = 28) or placebo (n = 24). Sixteen subjects were withdrawn from the study; 12 (43%) were from the treatment group (mainly for anemia [7 patients]) and 4 (17%) were from the control group. In the treated group, serum HCV RNA was undetectable in 9 patients (32%) at the end of treatment and in 6 (21.4%) at the end of the follow-up period, whereas no patient in the control group lost HCV RNA at any point (P = .036 at the end of follow-up). However, no significant histologic improvement was noted.
Overall, the combination of IFN alfa-2b plus ribavirin induced an SVR in 21% of transplant recipients with recurrent hepatitis C. However, 43% discontinued therapy because of adverse events (primarily severe anemia). Despite the low rates of sustained viral eradication in these patients, as reported by Samuel and other investigators, Narayanan Menon et al identified a subgroup of patients who demonstrated improved fibrosis scores despite failure to eradicate the virus. This suggests that some patients may benefit from maintenance therapy and emphasizes the benefit of performing pretreatment and posttreatment biopsies in this group of patients.
Two 2003 pilot studies, by Mukherjee et al and Rodriguez-Luna et al, reported on the use of PEG-IFN alfa-2b and ribavirin in these patients, and sustained eradication rates were less than 30%. Currently, no evaluations of PEG-IFN alfa-2b and ribavirin for recurrent HCV infection or randomized studies using PEG-IFN and ribavirin have been reported in this cohort of patients.
Hepatitis C treatment in patients with normal liver enzyme levels
The treatment for these patients remains controversial because previous studies have demonstrated that they frequently have mild liver disease, do not tolerate therapy, or can develop new elevations in liver chemistry parameters after initiating treatment.
In 2003, Hui et al reported that ALT levels and histology findings are not well correlated and patients can have advanced fibrosis or cirrhosis in the presence of normal liver enzyme levels. In 2004, Jacobson et al reported that sustained HCV eradication rates in their patients with HCV infection and normal ALT values were comparable to patients with elevated liver enzyme levels. However, the authors used both high- (5 million U) and low-dose (3 million U) IFN with ribavirin in their study and only 1 patient had cirrhosis. The role of prior alcohol use on liver injury was not investigated, although all patients abstained from alcohol for at least 12 months.
Future trials will most likely evaluate PEG-IFN with ribavirin in this cohort of patients and, hopefully, will adjust for confounders such as alcohol use.
Treatment of decompensated cirrhotic patients awaiting LT
The aim of treating decompensated cirrhotic patients is to achieve sustained viral eradication prior to LT in an attempt to prevent recurrent HCV infection. However, this intervention is not recommended outside clinical trials because, as reported by Crippin et al in 2002, the risks of treatment can outweigh the benefits. In 2004, Everson reported that although viral titers may decrease during treatment and possibly diminish the severity of recurrent HCV infection, complications and successful eradication are less likely in patients with more advanced liver disease.
HCV treatment in patients actively engaging in alcohol and injection drug use
In 1998, Wiley et al reported that because of the strong association between alcohol use and rapid liver fibrosis, hepatoma, and deleterious effects on treatment response, complete alcohol abstinence is recommended during treatment.
As reported by Strader et al in 2004, the practice guidelines of the American Association for the Study of Liver Diseases recommend that HCV treatment should not be withheld from persons who use illicit drugs or are on a methadone maintenance program, provided they are willing to maintain close monitoring, including practicing contraception. The complexity of HCV treatment in these patients is aided by a multidisciplinary team approach composed of physicians and drug abuse and psychiatric counselors.
Effect of IFN on HCC recurrence
In 2002, Hayashi and Kasahara noted that exposure to IFN, irrespective of HCV eradication status, was associated with a reduced incidence of HCC. An important randomized study by Kubo et al, first conducted in 1996 with follow-up in 2002, also demonstrated that the administration of IFN to patients undergoing liver resection for HCC was associated with reduced tumor recurrence and improved survival. Although IFN may have a role in reducing the incidence of HCC, which subgroup of HCV patients are most likely to benefit remains unclear.
Surgical Care: Consultation with a surgeon may be necessary for patients in whom hepatic resection for HCC or LT is being considered.
Diet: No special diet is recommended unless a patient has developed decompensated cirrhosis.
Combination therapy with PEG-IFN alfa and the nucleoside analog ribavirin is the current standard of care in patients infected with HCV. Patients with HCV genotype 1 have a much less favorable response to therapy and are treated for 12 mo, compared with patients infected with genotypes 2 and 3, in whom a 6-mo course of therapy is sufficient. If viremia is present after 6 mo, additional therapy has a negligible incremental benefit, and treatment should be stopped in all patients regardless of the viral genotype. With HIV co-infection, all patients with a response to therapy at the end of 6 mo should receive an additional 6 mo of combination therapy regardless of the genotype. Patients with acute HCV infection should be treated for 6 mo.
PATIENT EDUCATION
o Avoid sharing razors, tooth brushes and nail clippers
o Wash and cover cuts and bruises
o Proper use and disposal of needles
o Proper hygiene, particularly food handlers
o Sexual transmission low, but does occur
DRUG(S) OF CHOICE
o Acute hepatitis C: Antiviral therapy is highly effective for acute infections. Interferon-alfa 5 mg SC or IM daily for HCV-RNA for 4 weeks followed by 3 times per week for 20 weeks.
o Chronic hepatitis C: pegylated interferon + ribavirin
? Pegylated interferon-alpha 2b 1.5 mcg/kg/week
? Pegylated interferon-alpha 2a 180 mcg/week
? Ribavirin 800-1200 mg po bid in combination with pegylated interferon
Contraindications: Interferon: platelet count < 50,000. Mouse immunoglobulin, egg protein or neomycin allergy. Corticosteroids may add to morbidity/increased mortality.
Precautions:
o Other disorders of coagulation, myelosuppression, seizures, depression (esp suicide ideation), pregnancy,
fertile age group, lactation
o Ribavirin may induce hemolytic anemia (hemoglobin 2 gm/dL below pretreatment) is common. Avoid in
pregnancy.
o Increased serum triglycerides may occur during IFN therapy; may cause abnormal ALT. Measure HCV-RNA
to assess response in such patients.
o Psychiatric evaluation may be prudent prior to IFN treatment
PATIENT MONITORING
o Serial measurement of serum AST/ALT
o Appropriate serum viral markers useful for evaluation of recovery or progression
o Liver biopsies in chronic disease; in acute cases if diagnosis remains in doubt
o Monitor for metabolic complications
o WBC, platelets with interferon-alfa therapy
o Lower viral load, genotypes 2 and 3 and absence of cirrhosis are predictors of favorable therapeutic response.
Undetectable HCV-RNA (quantitative serum HCV-RNA) at 12 weeks is associated with sustained response.
Persistently positive HCV-RNA at 24 weeks indicates lack of response; prolonged course is unlikely to be
beneficial.
o Monitor for hepatic decompensation (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, etc) in cirrhotics
o Goal of therapy is eradication of hepatitis C virus; HCVRNA test should become persistently undetectable
o Early virologic response is defi ned as =2 log decrease in HCV-RNA level after 12 weeks of treatment
o In patients with cirrhosis the risk of hepatic cellular carcinoma is high (20% life-time risk). Monitor for
hypervascular lesions by imaging (ultrasound, helical CT) every 6 months.
PREVENTION/AVOIDANCE
o No specifi cs on prevention/avoidance
o Maximum infectivity 2 weeks before jaundice
POSSIBLE COMPLICATIONS
o Acute or subacute necrosis, chronic hepatitis, hepatic failure
o Primary liver cancer risk
o HCV-associated cirrhosis: 1-3% per year, lifetime risk 20%. Cirrhosis patients need surveillance for hepatocellular carcinoma.
EXPECTED COURSE/PROGNOSIS
o Severity of hepatic encephalopathy best predictor of poor survival in hepatic failure
o In HCV, regardless of severity:
? >80% progress to chronic hepatitis
? 20-50% to cirrhosis, and some, liver failure
? Typically slow progression 10-30 years
? May progress to HCC, but IFN may decrease HCC risk
? Associated with type II AI
? Chronic HCV unlikely to clear HCV-RNA spontaneously
? HCV after needlestick, usually sustained IFN response
? Final phase HCV rare cause of fulminant hepatic failure
o Alcohol increases severity of chronic HCV
Others: Alcohol abuse a major factor for chronic liver disease from HCV. Measure viral biochemical markers
in patients with alcoholic liver disease (especially anti-HCV).